Because of the delay, innovative cancer therapies remain out of reach for patients (Ph. Magnific)

Because of the delay, innovative cancer therapies remain out of reach for patients (Ph. Magnific)

Healthcare

Italy Left €3 Billion in Innovative Drug Funding Unspent as Cancer Patients Wait for Treatment

In some regions, patients wait up to 400 days to gain access to new therapies after they are approved for reimbursement. At its national congress, Italy’s medical oncology association calls for stronger oversight and streamlined procedures.

Francesca Ferri

The drug exists. It is innovative. It may have taken years of research to develop, but it is now on the market, and its effectiveness has been demonstrated. For a cancer patient, it represents a new source of hope: the chance to try a different treatment.

But that treatment does not always reach patients in time. Access is not guaranteed for everyone, and the process moves at very different speeds from one region to another.

Italy faces a troubling paradox: between 2018 and 2025, €3 billion in funding from the Innovative Medicines Fund went unused. The fund was created to ensure that patients across the country have timely, equitable access to high-value drug therapies without placing an additional burden on the regular budgets of individual local health authorities or regional governments.

The trend is getting worse. In 2018, 91% of the available funding was spent. By 2025, that figure had fallen to just 53% — barely more than half.

The problem is particularly serious because most of the treatments covered by the fund are cancer drugs. In 2025, 31 of the 55 approved indications were for oncology treatments, accounting for €353 million — more than half of the €700 million spent that year.

As a result, innovative cancer therapies remain out of reach for patients, while access varies widely across the country. The time between reimbursement approval by the Italian Drug Administration (AIFA) and the awarding of a procurement contract can range from 100 to 400 days, depending on the region. The national average is 165 days.

The warning comes from the 28th national congress of the Italian Association of Medical Oncology (AIOM), which opens in Rome on Nov. 13. This year’s theme, “Equitable Innovation,” underscores the need to eliminate persistent disparities in access to treatment.

There are several reasons for the delays. “On the one hand, there are still 21 different regional pathways, multiple procurement models and local organizational decisions, all of which contribute to unequal access,” AIOM says. “On the other, the length of time a drug remains in the fund can also have an impact. Recognition of a drug’s therapeutic innovation status is limited to a maximum of three years, with no possibility of extension, even when no more effective treatments are available.”

Adding insult to injury, the failure to use the available resources is now leading to cuts in the fund itself. Italy’s 2026 budget law provides for an annual reduction of €140 million starting in 2026.

AIOM is calling for a new framework for managing innovation that would remove local bureaucratic and administrative barriers to making new therapies available without delay and, in certain cases, allow drugs to remain in the fund for up to five years.

“Innovation can reach its full potential only if all citizens can benefit from it equally, regardless of where they live or receive treatment,” said Massimo Di Maio, AIOM’s President. “Italy was among the first countries in the world to establish a comprehensive regulatory framework for evaluating innovative medicines. When AIFA grants a drug full innovation status, it is supposed to receive direct access to the fund’s resources and be automatically included in regional drug formularies. In practice, however, drugs that should be immediately available to all patients are, in some cases, still out of reach.”

The allocation of funds is based on dispensing data recorded in AIFA’s monitoring systems, but delays can occur in activating the required drug registries.

“Reports from AIFA to the regions are still too infrequent,” Di Maio continued. “At the regional and local levels, hospitals are not receiving monthly data on the use of the fund quickly enough. These information gaps make it difficult to plan spending and hospital activities effectively. As a result, regional expenditures are not properly tracked and reimbursed in a timely manner. Moreover, some regions continue to impose additional hurdles even after AIFA has published its decision granting a drug full innovation status in the Official Gazette. These include restricting the number of centers authorized to prescribe the drug, introducing different procurement procedures, requiring additional institutional approvals or centralizing parts of the process.”

The result is a substantial regional disparity in how quickly patients can access treatments covered by the fund. Sicily, Campania and Tuscany are among the fastest-moving regions, while Abruzzo, Marche and Sardinia are among the slowest.

“We have built a system capable of recognizing and funding innovation. Now we must make it better equipped to support it over time,” said Robert Nisticò, President of the Italian Drug Administration. “In oncology, the value of a treatment is not exhausted by the evidence available at the time reimbursement is approved. Knowledge evolves, new benefits emerge, and we gain a better understanding of which patients are most likely to benefit. Our decisions must be able to keep pace with these developments, including through assessment and negotiation tools that increasingly take into account outcomes in everyday clinical practice.

“National recognition of a new treatment option must translate into effective access, without regional disparities. At AIFA, we understand that recognizing the value of innovation is only part of our responsibility. The other part is helping create the conditions that turn that recognition into a real treatment opportunity for every patient, wherever they live.”

Once the 36-month period expires, a drug remains eligible for reimbursement, but its cost is no longer covered by the fund. Instead, it is transferred to regional direct-purchase budgets and counts toward the spending cap for hospital pharmaceuticals.

“Innovation should not have an expiration date that is disconnected from its clinical value,” said Rossana Berardi, AIOM’s President-Elect. “In oncology, three years may not be enough to fully assess the benefits of a new treatment, particularly when its results become clearer over time. That is why we are calling for drugs in the Innovative Medicines Fund to be allowed to remain covered for up to five years when specific clinical and scientific conditions are met.”

Funding innovation is not enough, Berardi added. To make new treatments genuinely accessible, she outlined several priorities: “We need clear national rules, firm deadlines for activating prescribing centers and procurement procedures, AIFA registries that are operational from the moment reimbursement is approved, and transparent monitoring tools that clinicians can also access. We are not asking for fewer checks, but for more effective oversight and simpler procedures. Our goal must be clear: ensuring that the right to the best possible treatment does not depend on the region where a patient lives or on bureaucratic delays.”